ALTOPREV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALTOPREV (ALTOPREV).
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.
| Metabolism | Primarily hepatic via CYP3A4; also conjugated by glucuronidation. Metabolites include active beta-hydroxy acid. |
| Excretion | Renal (10% as active metabolites, 83% as inactive metabolites in urine); fecal (5%) |
| Half-life | 14 hours (terminal); extended-release formulation allows once-daily dosing |
| Protein binding | 91-95% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | 0.96 L/kg; indicates distribution into extravascular tissues |
| Bioavailability | 14-26% for extended-release tablets; food increases rate but not extent of absorption |
| Onset of Action | 2-4 weeks for LDL-C reduction; maximal effect at 4-6 weeks |
| Duration of Action | 24 hours; once-daily dosing due to extended-release formulation |
Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | eGFR 30-80 mL/min: No adjustment. eGFR <30 mL/min: Use with caution, max dose 20 mg/day. |
| Liver impairment | Contraindicated in active liver disease or unexplained persistent transaminase elevations. Child-Pugh Class A: No dose adjustment. Child-Pugh Class B or C: Not recommended (no data). |
| Pediatric use | Not approved for patients <20 years (safety and efficacy not established). |
| Geriatric use | Start at low end of dosing range (20 mg/day) due to increased risk of myopathy; monitor renal function and muscle symptoms. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALTOPREV (ALTOPREV).
| Breastfeeding | Contraindicated in breastfeeding. HMG-CoA reductase inhibitors may reduce cholesterol levels in breast milk, potentially adverse effects on infant lipid metabolism. M/P ratio not established for lovastatin; limited data suggest low excretion, but risk outweighs benefit. |
| Teratogenic Risk | FDA Pregnancy Category X. Contraindicated in pregnancy due to risk of fetal harm (HMG-CoA reductase inhibition may interfere with cholesterol synthesis necessary for fetal development). First trimester: high risk of congenital anomalies, including CNS and skeletal defects. Second and third trimesters: continued risk of fetal toxicity; placental transfer demonstrated in animal studies. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Active liver disease or unexplained persistent transaminase elevations","Hypersensitivity to lovastatin or any component","Pregnancy","Lactation","Concurrent use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat)"]
| Precautions | ["Myopathy/rhabdomyolysis risk, especially with concurrent use of CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors, grapefruit juice)","Hepatic enzyme elevations (monitor transaminases before and during therapy)","Use with caution in patients with renal impairment","Avoid in pregnancy and lactation"] |
| Food/Dietary | Grapefruit juice increases lovastatin blood levels and risk of toxicity. Avoid grapefruit products. High-fat meals may increase absorption; take with evening meal for optimal effect. |
Loading safety data…
| Fetal Monitoring | Not applicable as drug is contraindicated in pregnancy. If inadvertent exposure, monitor for fetal growth parameters, congenital anomalies (via ultrasound), and maternal hepatic function (ALT, AST). No specific monitoring recommendations for continuation. |
| Fertility Effects | No known adverse effects on fertility in animal studies. In humans, insufficient data; theoretical concern for sperm quality reduction due to cholesterol synthesis inhibition, but not confirmed. Discontinuation should be considered in patients planning pregnancy. |
| Clinical Pearls | ALTOPREV (lovastatin extended-release) should be taken with the evening meal to maximize absorption. Avoid grapefruit juice. Monitor liver function and creatine kinase. If used with fibrates, caution for myopathy/rhabdomyolysis. Not recommended in severe renal impairment (CrCl <30 mL/min). |
| Patient Advice | Take exactly as prescribed, once daily with the evening meal. · Avoid grapefruit and grapefruit juice during treatment. · Report unexplained muscle pain, tenderness, or weakness. · Avoid alcohol consumption; inform your doctor if you have liver disease. · Routine blood tests are needed to monitor liver function and cholesterol levels. |